Read by QxMD icon Read

Clinical & Translational Oncology

A M García Vicente, B González García, M Amo-Salas, I García Carbonero, J Cassinello Espinosa, J L Gómez-Aldaraví Gutierrez, L Suarez Hinojosa, Á Soriano Castrejón
AIM: To establish the utility of baseline 18 F-Fluorocholine (FCH) PET/CT and bone scintigraphy (BS) in the outcome prediction of patients with castration-resistant prostate cancer and bone metastases (CRPC-BM) treated with 223 Ra. METHODS: Prospective, multicenter and non-randomized study (ChoPET-Rad study). FCH PET/CT and BS were performed before the initiation of 223 Ra (basal FCH PET/CT and BS). Bone disease was classified attending the number of lesions in baseline BS and PET/CT...
July 13, 2018: Clinical & Translational Oncology
X Liu, K-M Chu
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. However, the development of molecular markers, especially circulating biomarkers, remains largely undone for the prognosis of GIST. We discussed the clinical-pathological characteristics of GIST and identified potential biomarkers for guidance of therapy and prognosis of GIST. Around 90% of GISTs contain mutations in KIT or PDGFRA and the remaining 10% of GISTs are wild-type. Recent studies have indicated that various DNAs and miRNAs could serve as potential biomarkers for prognosis of GIST, including KIT, PDGFRA, other DNAs (such as BRAF, SDH, SETD2 and ROR2), and microRNAs (miRNAs)...
July 12, 2018: Clinical & Translational Oncology
X Zhang, J Zhou, D-D Zhu, J Huang, J-H Sun, T-F Li, C-S Shi, Z-C Sun, Q-M Hou, Z-Y Peng, W-Q Yu, J-S Ji, W-J Gu, G-H Zhou, X-X Xie, X-H Guo, G-H Cao, Z-H Yu, H-H Xu, J Fang, S-H Ying, W-H Hu, W-B Ji, J Han, X Wu, J-P Zheng, J Luo, Y-T Chen, T-Y Hu, L Li, H-J Hu, H-J Du, G-L Shao
PURPOSE: To assess the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in liver cancer patients with different times of previous conventional transarterial chemoembolization (cTACE) treatments. METHODS: 367 liver cancer patients about to receive DEB-TACE treatment were enrolled in this prospective cohort study. All patients were divided into no previous cTACE group (NPC group), 1-2 times previous cTACE group (PC group) and triple or above previous cTACE group (TPC group) according to the times of previous cTACE treatments...
July 12, 2018: Clinical & Translational Oncology
F Couñago, G Sancho, A Gómez-Iturriaga, I Henríquez
PURPOSE: To investigate patterns of practice among Spanish radiation oncologists in the use of multiparametric magnetic resonance imaging (mpMRI) for the treatment of prostate cancer (PCa). We evaluated (1) access to mpMRI, (2) current clinical practices, and (3) physician expectations of mpMRI. METHODS: Cross-sectional survey of 118 radiation oncologists at 75 Radiation Oncology (RO) departments in Spain. RESULTS: A total of 55 radiation oncologists from 52 RO departments (52/75; 69%) completed the survey...
July 10, 2018: Clinical & Translational Oncology
J Aparicio, J Terrasa
No abstract text is available yet for this article.
July 10, 2018: Clinical & Translational Oncology
J Garde-Noguera, P Martin-Martorell, M De Julián, J Perez-Altozano, C Salvador-Coloma, J García-Sanchez, A Insa-Molla, M Martín, X Mielgo-Rubio, S Marin-Liebana, A Blasco-Cordellat, S Blasco-Molla, R Gironés, D Marquez-Medina, F Aparisi, M C Bas Cerda, S Macia-Escalante, A Sánchez, O Juan-Vidal
Clinical and Translational Oncology.
July 9, 2018: Clinical & Translational Oncology
J Wei, T Yao, Y Wang, L Li, C Pan, N Zhang
AIM: To study the prognostic factors of gastric cancer (GC) patients who were classified with stage III disease according to the newest TNM classification. METHODS: This study retrospectively enrolled 279 patients who underwent radical gastrectomy from January 2012 to December 2014 at our hospital and who were diagnosed with stage III GC according to the new 8th edition of the TNM classification. The patient data that were collected included age, sex, pathological parameters, survival, lymph node ratio, neo-adjuvant chemotherapy with oxaliplatin and S-1, and operation type...
July 2, 2018: Clinical & Translational Oncology
O Abdel-Rahman
PURPOSE: To assess the impact of relative dosing intensity (RDI) on the outcomes of breast cancer patients referred for adjuvant anthracycline-taxane chemotherapy. METHODS: This is a secondary analysis of the outcomes of patients in the comparator arm of the BCIRG005 study who received adjuvant adriamycin/cyclophosphamide (AC)-docetaxel regimen. Overall survival was assessed according to RDI through Kaplan-Meier analysis. Univariate and multivariate analyses of parameters affecting overall survival were then conducted through Cox regression analysis...
June 28, 2018: Clinical & Translational Oncology
G Liu, F Fei, J Qu, X Wang, Y Zhao, Y Li, S Zhang
PURPOSE: The aim of this study is to explore the roles of β-catenin, decorin, septin-7, and S100A10 expression in colorectal cancer development. METHODS: Twenty-five BALB/c mice were divided into five groups; four groups were administrated N,N-dimethylhydrazine for 0, 10, 15, and 20 weeks, and one group was administrated normal saline for 20 weeks. The colons were collected for histopathological analysis. Protein samples prepared from the frozen colon tissues of mice treated with N,N-dimethylhydrazine for the different time points were evaluated using the isobaric tags for relative and absolute quantification (iTRAQ) labeling technique coupled with the 2D liquid chromatography-tandem mass spectrometry analysis...
June 28, 2018: Clinical & Translational Oncology
N Sharma, M M Baruah
MicroRNAs (miRNAs) are short, non-coding, conserved, oligonucleotides that are regulatory in nature and are often dysregulated in many cancers including prostate cancer. Depending on the level of complementarity between the miRNA and mRNA target, they can either inhibit translation or degrade the target mRNA. MiRNAs expression is specific to the type of cancer, its stage and level of metastasis, making miRNAs potential stage-specific biomarkers of cancer. Recent research has shown that these miRNAs have the potential to be a diagnostic and prognostic non-invasive biomarker for various cancers including prostate cancer...
June 27, 2018: Clinical & Translational Oncology
H Shuang, J Feng, C Caineng, J Qifeng, J Tin, C Yuanyuan, C Xiaozhong
BACKGROUND: To explore the efficacy and patterns of treatment failure of radical radiotherapy in newly diagnosed oligo-metastatic nasopharyngeal carcinoma patients. METHODS: We included 39 newly diagnosed oligo-metastatic nasopharyngeal carcinoma patients who received radical radiotherapy and chemotherapy in Zhejiang Cancer Hospital. Treatment and prognosis information were collected. The Kaplan-Meier methods and Cox proportional hazards models were used to calculate survival rates and analyze prognostic factors...
June 25, 2018: Clinical & Translational Oncology
R Colomer, I Aranda-López, J Albanell, T García-Caballero, E Ciruelos, M Á López-García, J Cortés, F Rojo, M Martín, J Palacios-Calvo
On page 5 of the article, in the last paragraph of the section "Prognostic genetic platforms: molecular phenotypes and translation to the clinic" a relevant discrepancy between the text and Table 1 could be misunderstood, therefore the paragraph was corrected.
June 18, 2018: Clinical & Translational Oncology
L de la Cruz-Merino, N Palazón-Carrión, F Henao-Carrasco, E Nogales-Fernández, M Álamo-de la Gala, A Vallejo-Benítez, M Chiesa, V Sánchez-Margalet
Immunology and immunotherapy of cancer is an expanding field in oncology, with recent great achievements obtained through the new successful approaches implemented to circumvent immune evasion, which is undoubtedly considered a novel hallmark of cancer. Translational research in this topic has revealed targets that can be modulated in the clinical setting with new compounds and strategies. Like most of the tumors, breast cancer is considered a complex and heterogeneous disease in which host immune responses have been also recently demonstrated of critical relevance...
June 18, 2018: Clinical & Translational Oncology
T Karantanos, S Karanika, B Seth, G Gignac
INTRODUCTION: The neutrophil-to-lymphocyte (ANC/ALC) ratio is associated with worse prognosis in patients with NSCLC on immunotherapies, but the role of ALC remains unclear. The previous radiation therapy causes lymphopenia, and given approaches of combining radiation with immunotherapies, it is critical to better understand the impact of peripheral lymphocytes. PATIENTS AND METHODS: We evaluated retrospectively 22 patients with advanced NSCLC treated with nivolumab at Boston Medical Center from January 2014 to September 2016 and correlated the peripheral blood counts with the overall survival (OS) and overall time on treatment...
June 13, 2018: Clinical & Translational Oncology
M Marín, C Gudiol, F Castet, M Oliva, I Peiró, C Royo-Cebrecos, J Carratalà, R Mesia
PURPOSE: To assess the impact of bloodstream infection (BSI) in patients with head and neck cancer (HNC) in the cetuximab era. METHODS: We prospectively analysed the epidemiology, microbiology and outcomes of 51 BSI episodes occurring in 48 patients with HNC (2006-2017). We performed a retrospective matched-cohort study (1:2) to determine the risk factors for BSI. Finally, we compared patients who died with those who survived to identify risk factors for mortality...
June 11, 2018: Clinical & Translational Oncology
L-L Deng, H-B Deng, C-L Lu, G Gao, F Wang, Y Yang
PURPOSE: Detecting different molecular markers in primary tumors and metastases may provide therapeutic information. Here we investigated differences between primary tumors and four metastatic sites of lung adenocarcinoma in the biomarkers' features and discussed potential therapeutic implications. METHODS: A total of 228 patients with metastatic lung adenocarcinoma were analyzed for EGFR, KRAS, BRAF and PIK3CA mutations detected by xTAG liquidchip technology (xTAG-LCT), as well as ERCC1, TYMS, RRM1, TUBB3, STMN1, TOP2A and VEGFR1-3 mRNA expression detected by branched DNA-liquidchip technology (bDNA-LCT)...
June 11, 2018: Clinical & Translational Oncology
F Bartel, M van Herk, H Vrenken, F Vandaele, S Sunaert, K de Jaeger, N J Dollekamp, C Carbaat, E Lamers, E M T Dieleman, Y Lievens, D de Ruysscher, S B Schagen, M B de Ruiter, J C de Munck, J Belderbos
BACKGROUND: Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) techniques have been developed to reduce radiation damage to the hippocampus. An inter-observer hippocampus delineation analysis was performed and the influence of the delineation variability on dose to the hippocampus was studied. MATERIALS AND METHODS: For five patients, seven observers delineated both hippocampi on brain MRI. The intra-class correlation (ICC) with absolute agreement and the generalized conformity index (CIgen ) were computed...
June 6, 2018: Clinical & Translational Oncology
S González-Moreno
No abstract text is available yet for this article.
June 6, 2018: Clinical & Translational Oncology
J Rubió-Casadevall, M Puig-Vives, M Puigdemont, L Vilardell, A Carbó-Bagué, R Marcos-Gragera, N Vilar-Coromina
INTRODUCTION: We conducted a population-based study on the Girona Cancer Registry (Spain) for the period 1994-2013 to determine patterns of change in the incidence of melanoma, which is increasing in many countries, and patient survival in our geographical area. MATERIALS AND METHODS: Using the standard registration rules for cancer registries, we calculated crude and standardized incidence rates as well as their trends. We also analysed the observed survival, 1-year conditioned survival and relative survival at 3, 5 and 10 years...
June 5, 2018: Clinical & Translational Oncology
H Ghaffari, J Beik, A Talebi, S R Mahdavi, H Abdollahi
Cancer stem cells (CSCs) have been identified as the main center of tumor therapeutic resistance. They are highly resistant against current cancer therapy approaches particularly radiation therapy (RT). Recently, a wide spectrum of physical methods has been proposed to treat CSCs, including high energetic particles, hyperthermia (HT), nanoparticles (NPs) and combination of these approaches. In this review article, the importance and benefits of the physical CSCs therapy methods such as nanomaterial-based heat treatments and particle therapy will be highlighted...
June 4, 2018: Clinical & Translational Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"